This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor:—
In the clinical note, "Angranulocytosis Due to Administration of Salicylazosulfapyridine ( Azulfidine )," in The Journal, Jan. 16, p. 237, the authors declare, "We are aware of only one other occurrence of agranulocytosis associated with administration of this drug." Just prior to making this statement, they mention a case described by Levy in 1949 (reference 6), while the case to which they refer in their statement is one of which they were informed through a personal communication (reference 7).A report has been made by Evans and Ford (Studies of Bone Marrow in Immunological Granulocytopenia, A. M. A. Arch. Int. Med.101:244 [Feb.] 1958) of another such case, and there is, in addition to this, a fourth case which has been recorded in the literature. The first case occurred in a patient after he had been taking 4 Gm. of salicylazosulfapyridine daily in divided doses for about two
Trimble GX. REVIEWS OF LITERATURE. JAMA. 1960;172(16):1857. doi:10.1001/jama.1960.03020160129023